Precigen Inc. Common Stock (PGEN)

FairStock Score: 22/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach a clinical-stage biotech with Graham's caution: the asset is hope, not earnings. Precigen develops gene and cell therapies. In fiscal 2025, the year ended 2025-12-31, it reported revenue of $9.7 million and a net loss of $250.6 million, or diluted EPS of -$1.37. Trailing twelve-month free cash flow was -$115.2 million, a -4.3% FCF yield on the $2.7 billion market cap at the 2026-10-13 close. FairStock calculations show P/E -6.99, P/B 62.33, ROE -837.07%, ROCE -18.14%, debt-to-equity 2.26, Altman Z-score -4.97, and a Piotroski F-score of 5/9. That is not a fortress balance sheet. The moat, if any, rests on proprietary AdenoVerse and UltraCAR-T platforms, but clinical-stage biotech has no durable pricing power until approval and commercialization. The latest fiscal Q2 2026, quarter ended 2026-06-30, is a bright spot: revenue of $55.0 million, net income of $20.1 million, diluted EPS $0.05, and a 36.51% net margin. Fiscal Q1 2026, quarter ended 2026-03-31, had revenue of $23.3 million and a net loss of $7.9 million. If Q2's profit is repeatable, the trajectory changes; if it is episodic, the stock at $7.48 offers little margin of safety. The FairStock score of 22/100 and Lynch category TURNAROUND—loss in latest year after earlier profits—capture the uncertainty.

In plain English: Precigen is a small biotech that develops gene and cell therapies. Its long record shows heavy losses and cash burn, but the latest three-month report in fiscal Q2 2026 showed a profit and much higher revenue than before. At $7.48, the stock looks expensive relative to the company's tiny annual revenue and history of losses, so the recent improvement needs to last to justify the price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer